Question 1

What is MK-677 (Ibutamoren)?

Accepted Answer

MK-677 (Ibutamoren) is a non-peptide, orally active growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release. Unlike injectable GHRPs, MK-677 is taken orally and has a long duration of action (approximately 24 hours), allowing once-daily dosing.

Question 2

What are the research benefits of MK-677 (Ibutamoren)?

Accepted Answer

Research on MK-677 (Ibutamoren) has investigated its potential effects in several areas, including: Oral administration (no injection required); Long-acting — once daily dosing; Studied for sustained GH and IGF-1 elevation; Researched for improved sleep quality and deep sleep. These findings are primarily from preclinical and animal studies unless otherwise noted. Results may not translate directly to humans.

Question 3

How does MK-677 (Ibutamoren) work?

Accepted Answer

MK-677 is a ghrelin mimetic that binds to GHS-R1a receptors, stimulating GH release from the pituitary. Its non-peptide structure allows oral bioavailability and a long half-life (~24 hours). It elevates GH and IGF-1 levels for sustained periods, and notably increases appetite through ghrelin receptor activation in the hypothalamus.

Question 4

What is the FDA/legal status of MK-677 (Ibutamoren)?

Accepted Answer

MK-677 (Ibutamoren) is currently in clinical trials and is not yet FDA-approved for general use. It may only be used in the context of approved clinical trial protocols. It is not available for general consumer purchase in the United States.

Question 5

What are the known risks or side effects of MK-677 (Ibutamoren)?

Accepted Answer

Based on available research, MK-677 (Ibutamoren) has been associated with the following in study settings: Increased appetite and hunger; Water retention and bloating; Potential insulin resistance with prolonged use; Lethargy and drowsiness. Long-term safety data in humans is limited or absent for most research peptides. This should not be taken as a complete safety profile.

Question 6

Where can I find published research on MK-677 (Ibutamoren)?

Accepted Answer

Published research on MK-677 (Ibutamoren) can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for "MK-677 (Ibutamoren)" or its aliases (Ibutamoren, Oratrope) to find peer-reviewed studies. PEP.WIKI aggregates key studies with abstracts and study type classifications on each compound's research page.

MK-677 (Ibutamoren)

Overview

Mechanism of Action

Key Research Benefits

Clinical Evidence Summary

Key Studies / PubMed References

Hepatotoxicity induced by MK-677.

A GH Secretagogue Receptor Agonist (LUM-201) Elicits Greater GH Responses than Standard GH Secretagogues in Subjects of a Pediatric GH Deficiency Trial.

LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.

Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control.

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

Side Effects & Safety

Known Interactions

Frequently Asked Questions

Research Disclaimer